Apogee Therapeutics (APGE) CMO Carl Dambkowski Exercises Options, Sells Shares

What Happened

• Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, exercised stock options to acquire 4,125 shares at an exercise price of $22.86 (cost ≈ $94,298) on August 5, 2026. The filing also records a corresponding derivative disposition of 4,125 shares at $0.00 (part of the exercise/settlement reporting). On the same day he sold 5,500 shares in an open‑market transaction at $134.17 per share for proceeds of approximately $737,935. The sale was executed under a pre-established plan.

Key Details

• Transaction date: August 5, 2026 (reported via Form 4 filed August 7, 2026).
• Option exercise: 4,125 shares acquired at $22.86 (≈ $94,298).
• Derivative disposition: 4,125 shares reported at $0.00 (related to the exercise/settlement).
• Open‑market sale: 5,500 shares at $134.17 (≈ $737,935).
• Shares owned after transaction: not specified in the filing.
• Footnotes: (F1) Sale executed pursuant to a Rule 10b5-1 trading plan adopted Sept 22, 2025. (F2) The option exercised is part of a larger grant representing the right to purchase 175,345 shares that vest in 48 monthly installments through Dec 18, 2027, subject to continued service.
• Timeliness: Form 4 was filed two days after the trade date, consistent with the Form 4 reporting deadline.

Context

• This filing shows an option exercise (insider acquiring shares via exercising options) combined with an open‑market sale. The presence of a Rule 10b5‑1 plan means the sale was pre‑planned and not necessarily a discretionary trade by the insider at the time of sale. The zero‑price derivative disposition is a common way to report shares surrendered or netted in connection with an exercise/settlement and does not by itself indicate an independent sale.